Rege Nephro Co., Ltd.

Rege Nephro Co., Ltd. is a clinical-stage biotech company founded in 2019, headquartered in Japan. The company is focused on developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD). With 13 million CKD patients in Japan, including 340,000 severe CKD patients on artificial dialysis, Rege Nephro aims to address the unmet medical needs in this space. Their approach involves the use of nephron progenitor cells derived from iPS cells for a potential curative treatment for CKD.

Healthcare Innovation's Venture Round investment at 01 January 2022 in Rege Nephro signifies a vote of confidence in the company's mission and technology. Given the substantial $12 billion healthcare cost of dialysis in Japan, representing 4% of the total healthcare cost, addressing CKD with innovative therapies has significant potential impact. This aligns with the company's vision to offer a transformative solution in the biotechnology and manufacturing sectors, ultimately contributing towards improving patient outcomes and reducing healthcare burdens.